What is he best known for?
The fields of study he is best known for:
Gilles Divita mainly investigates Biochemistry, Peptide, Gene delivery, Internalization and Molecular biology.
His work on DNA, Phosphorylation and Kinase as part of general Biochemistry research is frequently linked to Isomerization, bridging the gap between disciplines.
His Peptide research is multidisciplinary, relying on both Nucleic acid, Cell membrane, Oligonucleotide and Signal peptide.
His Gene delivery study combines topics from a wide range of disciplines, such as Plasmid and NLS.
His Internalization study incorporates themes from Pharmacology and Drug delivery.
His studies in Molecular biology integrate themes in fields like Cell culture, Messenger RNA, RNA-binding protein, THO complex and Cell biology.
His most cited work include:
- A peptide carrier for the delivery of biologically active proteins into mammalian cells. (922 citations)
- Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics (728 citations)
- A new peptide vector for efficient delivery of oligonucleotides into mammalian cells (479 citations)
What are the main themes of his work throughout his whole career to date?
Gilles Divita mainly focuses on Biochemistry, Peptide, Cell biology, Stereochemistry and Reverse transcriptase.
He integrates many fields in his works, including Biochemistry and Amphiphile.
His biological study spans a wide range of topics, including Nucleic acid, Biophysics, Cell membrane, Oligonucleotide and Gene delivery.
Gilles Divita has researched Cell biology in several fields, including Ubiquitin binding, In vivo and Cyclin.
His In vivo research incorporates themes from Drug delivery and Small interfering RNA.
His Reverse transcriptase research includes themes of In vitro, Protein subunit, Enzyme, Molecular biology and Viral replication.
He most often published in these fields:
- Biochemistry (43.33%)
- Peptide (34.17%)
- Cell biology (25.83%)
What were the highlights of his more recent work (between 2008-2020)?
- Peptide (34.17%)
- In vivo (10.00%)
- Nucleic acid (14.17%)
In recent papers he was focusing on the following fields of study:
His main research concerns Peptide, In vivo, Nucleic acid, Biophysics and Cell biology.
Biochemistry covers Gilles Divita research in Peptide.
His research in In vivo intersects with topics in Pharmacology, Drug, Cell-penetrating peptide and Small interfering RNA.
His study in Drug is interdisciplinary in nature, drawing from both In vitro and Liposome.
Gilles Divita has included themes like Molecule, Oligonucleotide, Intracellular and Nanocarriers in his Nucleic acid study.
The various areas that Gilles Divita examines in his Biophysics study include Nanoparticle and Molecular model.
Between 2008 and 2020, his most popular works were:
- Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics (728 citations)
- Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. (159 citations)
- Happy birthday cell penetrating peptides: already 20 years. (65 citations)
In his most recent research, the most cited papers focused on:
Gilles Divita spends much of his time researching In vivo, Peptide, RNA, In vitro and Ex vivo.
His work deals with themes such as Drug delivery, Internalization, Computational biology, Pharmacology and Cell-penetrating peptide, which intersect with In vivo.
The study incorporates disciplines such as Phospholipid, Transfection, Cell membrane, Transduction and Cell biology in addition to Peptide.
Gilles Divita interconnects Cell culture, Cancer research, Systemic administration and Cell growth in the investigation of issues within RNA.
His In vitro study incorporates themes from Reverse Transcription Process, Reverse transcriptase, Mutation, Complementary DNA and Viral replication.
His research integrates issues of Molecular biology and Cell in his study of Viral replication.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
